Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib, Open-label, Modular Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors

NCT07163481 is registered in ClinicalTrials.gov with Hunan Cancer Hospital as lead sponsor.

NCT NCT07163481
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07163481 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib, Open-label, Modular Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors
Lead sponsor
Hunan Cancer Hospital
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 31, 2025
Completion date
December 31, 2026
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stage iv (metastatic) breast cancer